Century Therapeutics, Inc.

    Jurisdiction
    United States
    ISIN
    US15673T1007 (IPSC)
    Sectors
    1. Healthcare
    2. Biotechnology

    Scores

    Fair value (Benjamin Graham formula)
    N/A
    Financial strength (Piotroski F-Value)
    5 / 9
    Fundamental strength relative to industry (Mohanram G-Value)
    3 / 7

    Profile

    Century Therapeutics, Inc., a biotechnology company, develops transformative allogeneic cell therapies for the treatment of solid tumor and hematological malignancies. Read full profile

    Fundamentals

    Net revenue
    €97.35M
    Gross margin
    97.2%
    EBIT
    -€27.77M
    EBIT margin
    -28.5%
    Net income
    -€19.86M
    Net margin
    -20.4%

    Statement period: - (published )

    Stock price

    Stock price loading... No stock price available Stock price provided by Lang & Schwarz Steigende Zinsen und niedrigere Bewertungen für Wachstumsaktien im Allgemeinen Eine Gewinnwarnung beim Konkurrenten Adyen signalisiert eine Abkühlung des europäischen Markts für Zahlungsdienstleistungen. Eine Gewinnwarnung von Wordline SA triggert einen massiven Kursverlust.

    Configure chart

    Adjust colors to be more accessible for red-green-colorblind users.
    Scale
    Moving average Display a moving average line on the chart.

    Dividends

    No dividend payouts

    Analyst ratings

    No analyst ratings available

    Insider Transactions

    Name Title Transaction Date Shares Price Value
    Carr Douglas SVP Finance & Operations -296 $0.53 -$156.88

    Investor transactions

    Name Shares Value Last change Change type
    Peter Brown 1.2M $564.21K -18K Sell

    Earnings Calls

    Add to watchlist

    Notifications